Palvella Advances Rare Skin Disease Pipeline with New Data at AAD Annual Meeting
Event summary
- Palvella presented two posters at the 2026 AAD Annual Meeting on March 27.
- Poster #76954 highlighted QTORIN™ rapamycin’s anhydrous gel formulation for mTOR-driven skin diseases.
- Poster #76929 detailed a qualitative study on the burden of porokeratosis from patient and caregiver perspectives.
- QTORIN™ rapamycin met its primary endpoint in the Phase 3 SELVA study for microcystic lymphatic malformations (p<0.001).
- Palvella plans to announce a fourth target clinical indication for QTORIN™ rapamycin in the second half of 2026.
The big picture
Palvella’s presentations at the AAD Annual Meeting underscore its focus on addressing unmet needs in rare dermatologic conditions. The company’s QTORIN™ platform aims to overcome formulation challenges with rapamycin, positioning it as a potential leader in treating mTOR-driven skin diseases. With no FDA-approved therapies for porokeratosis or microcystic lymphatic malformations, Palvella is carving out a strategic advantage in a high-barrier market.
What we're watching
- Clinical Progress
- Whether QTORIN™ rapamycin can maintain its efficacy across multiple rare skin diseases.
- Regulatory Pathway
- The pace at which Palvella advances QTORIN™ pitavastatin through Phase 2 trials for porokeratosis.
- Market Opportunity
- How the lack of FDA-approved therapies for rare skin diseases positions Palvella in a competitive niche.